✦ LIBER ✦

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck : An analysis of two Eastern Cooperative Oncology Group randomized trials

✍ Scribed by Athanassios Argiris; Yi Li; Arlene Forastiere

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 144 KB
Volume: 101
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20640

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel and irinotecan in recurrent or

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the Eastern Cooperative Oncology Group

✍ Athanassios Argiris; Ashley Buchanan; Bruce Brockstein; Jill Kolesar; Musie Gheb 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr

Final report of a phase II evaluation of

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)

✍ Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

A randomized Phase II trial of echinomyc

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)

✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

A phase II study of 5-fluorouracil, leuc

A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)

✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext